PolyActiva and RareSight collaborate to create innovative therapies for rare pediatric retinal diseases, aiming to transform ...

Once a drug target is identified, it often takes decades until a chemical compound is developed that can hit the bullseye and ...

Ultraviolet light causes damage to DNA, leads to cancer and photoaging: age spots and wrinkles. I was curious about this ...

Learn how moving beyond ELISA can streamline your cell line development and boost productivity without compromising results.

The best hair repair treatments for stronger, shinier hair, according to over 200 women. Why and when to turn to bond ...

A new technical paper titled “The van der Waals Gap: a Hidden Showstopper in Semiconductor Device Scaling” was published by ...

This dual cross-linking design lets the muscle switch stiffness on demand. In lab tests, its stiffness jumps from about 213 ...

The open-source model designs therapeutics across "any" modality with experimental validation for diverse real-world challenging targets.

PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes for patients with ocular conditions, and RareSight, Inc., an ...

A soft robotic system uses liquid crystal elastomers to merge shape shifting, gripping, and color change, demonstrating fully ...